Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025

Core Insights - Compugen Ltd. is set to present a pooled analysis of data from three Phase 1 trials of COM701 for treating heavily pretreated platinum-resistant ovarian cancer patients at ESMO 2025 in Berlin [1][2] Company Overview - Compugen is a clinical-stage cancer immunotherapy company that utilizes AI/ML for predictive computational drug target discovery [2] - The company has two proprietary product candidates in Phase 1 development: COM701, an anti-PVRIG antibody, and COM902, an antibody targeting TIGIT for solid tumors [2] - Compugen's pipeline includes early-stage immuno-oncology programs aimed at activating the immune system against cancer [2] - The company is headquartered in Israel with additional offices in San Francisco, CA, and its shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN [2]